VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1629-1634

  Schlingemann, Reinier O ^a,b   Van Noorden, Cornelis J F ^a   Diekman, Mattheus J M ^a   Tiller, Anna ^a   Meijers, Joost C M ^a   Koolwijk, Pieter ^c   Wiersinga, Wilmar M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; THROMBOCYTE FACTOR 4; VASCULOTROPIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; EX VIVO STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PLASMA; PROTEIN BLOOD LEVEL; SERUM; THROMBOCYTE ACTIVATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PLATELET ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84878255619     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1951     Document Type: Article

References (39)

1. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219-226 (Pubitemid 19136363)
2. Stehouwer CDA, Fischer HR, van Kuijk AWR, Polak BCP, Donker AJM. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995;44:561-564
3. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34:55-68 (Pubitemid 27261913)
4. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009;120:1266-1286
5. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009;335:165-189
6. Schlingemann RO, van Hinsbergh VW. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol 1997;81:501-512 (Pubitemid 27300078)
7. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997;94:663-668 (Pubitemid 27053690)
8. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-2190 (Pubitemid 28133134)
9. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-964 (Pubitemid 28101786)
10. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000;58:169-174 (Pubitemid 30113869)
11. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998;10:254-257 (Pubitemid 28227067)
12. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29 (Pubitemid 36207453)
13. Siemerink MJ, Augustin AJ, Schlingemann RO. Mechanisms of ocular angiogenesis and its molecular mediators. Dev Ophthalmol 2010;46:4-20
14. Asselbergs FW, de Boer RA, Diercks GF, et al. Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? Int J Cardiol 2004;93:211-215 (Pubitemid 38229589)
15. Stephan CC, Chang KC, LeJeune W, et al. Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Diabetes 1998;47:1771-1778 (Pubitemid 28476252)
16. Tilton RG, Kawamura T, Chang KC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997;99:2192-2202 (Pubitemid 27203775)
17. Hirata C, Nakano K, Nakamura N, et al. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun 1997;236:712-715 (Pubitemid 27384695)
18. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101:1219-1224 (Pubitemid 28145237)
19. McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999;5:21-24 (Pubitemid 29028484)
20. Zakareia FA. Correlation of peripheral arterial blood flow with plasma chemerin and VEGF in diabetic peripheral vascular disease. Biomarkers Med 2012;6:81-87
21. Nandy D, Mukhopadhyay D, Basu A. Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose. J Investig Med 2010;58:804-806
22. Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med 2010;267:385-393
23. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000;75:S56-S61 (Pubitemid 30205441)
24. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000;41:2115-2119 (Pubitemid 30450982)
25. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153:307-313, e2
26. Abdel Aziz MY, Ben Gharbia O, el-Sayed Mohamed K, Muchaneta-Kubara EC, el Nahas AM. VEGF and diabetic microvascular complications. Nephrol Dial Transplant 1997;12:1538
27. Burgos R, Simó R, Audí L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 1997;40:1107-1109 (Pubitemid 27381975)
28. Sharp PS, Al-Mrayat M, Valabhji J, Kearney TM, Wright D. Serum levels of vascular endothelial growth factor in diabetic subjects: the relationship with blood pressure. Diabetologia 1998;41:984-985 (Pubitemid 28365990)
29. Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr Res 1998;44:873-875 (Pubitemid 28543972)
30. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992;85:305-312
31. Kaplan KL, Owen J. Plasma levels of platelet secretory proteins. Crit Rev Oncol Hematol 1986;5:235-255 (Pubitemid 16005938)
32. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS ONE 2011;6:e19873
33. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl.):757-765
34. Roestenberg P, van Nieuwenhoven FA, Wieten L, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27:1164-1170 (Pubitemid 38579784)
35. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18
36. Peterson JE, Zurakowski D, Italiano JE Jr, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012;15:265-273
37. Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 2002;50:767-777 (Pubitemid 34721445)
38. Vuorela-Vepsäläinen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmäki E. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 1999;14:1346-1351 (Pubitemid 29224921)
39. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33:1529-1535